Numiera Therapeutics Inc.

Numiera is developing small-molecule therapies for oncology indications, including malignant brain tumors. It has FDA orphan designation to repurpose the CPT1 inhibitor etomoxir for patients with malignant glioma, including glioblastoma. Source

Keywords: small-molecule oncology malignant brain tumors etomoxir CPT1 glioblastoma malignant glioma Show all 7 keywords